Role of inflammatory cytokines in depression: Focus on interleukin-1β (Review)

Biomedical Reports

Volumn 6, Issue 1, 2017, Pages 15-20

  Farooq, Rai Khalid ^a   Asghar, Kashif ^b   Kanwal, Shahzina ^c   Zulqernain, Ali ^d  

^a National Institute of Heart Diseases National University of Medical Sciences   (Pakistan)

^b SHAUKAT KHANUM MEMORIAL CANCER HOSPITAL AND RESEARCH CENTRE   (Pakistan)

^c GUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH   (China)

^d UNIVERSITY OF SARGODHA   (Pakistan)

Author keywords

Cytokines; Depression; Interleukin 1 ; Neuroinflammation

Indexed keywords

AMINE; ANTIDEPRESSANT AGENT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 1BETA; MITOGEN ACTIVATED PROTEIN KINASE; PURINERGIC P2X7 RECEPTOR; SEROTONIN; TUMOR NECROSIS FACTOR;

AGE; BEHAVIOR; CYTOKINE PRODUCTION; DEPRESSION; DNA MICROARRAY; EPIGENETICS; GENE EXPRESSION PROFILING; HUMAN; HYPERACTIVITY; MYCOBACTERIUM BOVIS BCG; NERVE DEGENERATION; NERVOUS SYSTEM DEVELOPMENT; NERVOUS SYSTEM INFLAMMATION; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; SEROTONINERGIC SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; SUICIDAL IDEATION;

EID: 85019174065     PISSN: 20499434     EISSN: 20499442     Source Type: Journal    
DOI: 10.3892/br.2016.807     Document Type: Review

References (83)

1. Mathers CD and Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 3: e442, 2006.
2. Seligman ME and Csikszentmihalyi M: Positive psychology: an introduction. Springer Netherlands, Dordrecht, pp279-298, 2014.
3. Murphy DL, Cohen RM, Siever LJ, Roy B, Karoum F, Wyatt RJ, Garrick NA and Linnoila M: Clinical and laboratory studies with selective monoamine-oxidase-inhibiting drugs. Implications for hypothesized neurotransmitter changes associated with depression and antidepressant drug effects. Mod Probl Pharmacopsychiatry 19: 287-303, 1983.
4. Ader R and Cohen N: High time for psychoimmunology. Nature 315: 103-104, 1985.
5. Maes M: Evidence for an immune response in major depression: A review and hypothesis. Prog Neuropsychopharmacol Biol Psychiatry 19: 11-38, 1995.
6. Maes M, Berk M, Goehler L, Song C, Anderson G, Gałecki P and Leonard B: Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med 10: 66, 2012.
7. Skaper SD, Facci L and Giusti P: Neuroinflammation, microglia and mast cells in the pathophysiology of neurocognitive disorders: a review. CNS Neurol Disord Drug Targets 13: 1654-1666, 2014.
8. Maes M, Van de Vyvere J, Vandoolaeghe E, Bril T, Demedts P, Wauters A and Neels H: Alterations in iron metabolism and the erythron in major depression: Further evidence for a chronic inflammatory process. J Affect Disord 40: 23-33, 1996.
9. Smith RS: The macrophage theory of depression. Med Hypotheses 35: 298-306, 1991.
10. Patel A: Review: The role of inflammation in depression. Psychiatr Danub 25 (Suppl 2): S216-S223, 2013.
11. Dantzer R: Cytokine, sickness behavior, and depression. Immunol Allergy Clin North Am 29: 247-264, 2009.
12. Hart BL: Biological basis of the behavior of sick animals. Neurosci Biobehav Rev 12: 123-137, 1988.
13. Kent S, Bluthe RM, Dantzer R, Hardwick AJ, Kelley KW, Rothwell NJ and Vannice JL: Different receptor mechanisms mediate the pyrogenic and behavioral effects of interleukin 1. Proc Natl Acad Sci USA 89: 9117-9120, 1992.
14. Raison CL, Capuron L and Miller AH: Cytokines sing the blues: Inflammation and the pathogenesis of depression. Trends Immunol 27: 24-31, 2006.
15. Irwin M: Immune correlates of depression. Adv Exp Med Biol 461: 1-24, 1999.
16. Cruess DG, Douglas SD, Petitto JM, Have TT, Gettes D, Dubé B, Cary M and Evans DL: Association of resolution of major depression with increased natural killer cell activity among HIV-seropositive women. Am J Psychiatry 162: 2125-2130, 2005.
17. Evans DL, Ten Have TR, Douglas SD, Gettes DR, Morrison M, Chiappini MS, Brinker-Spence P, Job C, Mercer DE, Wang YL, et al: Association of depression with viral load, CD8 T lymphocytes, and natural killer cells in women with HIV infection. Am J Psychiatry 159: 1752-1759, 2002.
18. Pike JL and Irwin MR: Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder. Brain Behav Immun 20: 169-174, 2006.
19. Papanicolaou DA, Wilder RL, Manolagas SC and Chrousos GP: The pathophysiologic roles of interleukin-6 in human disease. Ann Intern Med 128: 127-137, 1998.
20. Liu Y, Ho RC and Mak A: Interleukin (IL)-6, tumour necrosis factor alpha (TNF-α) and soluble interleukin-2 receptors (sIL-2R) are elevated in patients with major depressive disorder: A meta-analysis and meta-regression. J Affect Disord 139: 230-239, 2012.
21. Brebner K, Hayley S, Zacharko R, Merali Z and Anisman H: Synergistic effects of interleukin-1β, interleukin-6, and tumor necrosis factor-α: Central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 22: 566-580, 2000.
22. Yudkin JS, Kumari M, Humphries SE and Mohamed-Ali V: Inflammation, obesity, stress and coronary heart disease: Is interleukin-6 the link? Atherosclerosis 148: 209-214, 2000.
23. Carvalho LA, Urbanova L, Hamer M, Hackett RA, Lazzarino AI and Steptoe A: Blunted glucocorticoid and mineralocorticoid sensitivity to stress in people with diabetes. Psychoneuroendocrinology 51: 209-218, 2015.
24. McInnis CM, Thoma MV, Gianferante D, Hanlin L, Chen X, Breines JG, Hong S and Rohleder N: Measures of adiposity predict interleukin-6 responses to repeated psychosocial stress. Brain Behav Immun 42: 33-40, 2014.
25. Ershler WB and Keller ET: Age-associated increased interleukin-6 gene expression, late-life diseases, and frailty. Annu Rev Med 51: 245-270, 2000.
26. Windham BG, Simpson BN, Lirette S, Bridges J, Bielak L, Peyser PA, Kullo I, Turner S, Griswold ME and Mosley TH: Associations between inflammation and cognitive function in African Americans and European Americans. J Am Geriatr Soc 62: 2303-2310, 2014.
27. Huber SA, Sakkinen P, Conze D, Hardin N and Tracy R: Interleukin-6 exacerbates early atherosclerosis in mice. Arterioscler Thromb Vasc Biol 19: 2364-2367, 1999.
28. Zhang T, Chen Y, Liu H, Zhou Z, Zhai Y and Yang J: Chronic unpredictable stress accelerates atherosclerosis through promoting inflammation in apolipoprotein E knockout mice. Thromb Res 126: 386-392, 2010.
29. Song C, Dinan T and Leonard BE: Changes in immunoglobulin, complement and acute phase protein levels in the depressed patients and normal controls. J Affect Disord 30: 283-288, 1994.
30. Yudkin JS, Yajnik CS, Mohamed-Ali V and Bulmer K: High levels of circulating proinflammatory cytokines and leptin in urban, but not rural, Indians. A potential explanation for increased risk of diabetes and coronary heart disease. Diabetes Care 22: 363-364, 1999.
31. Baker DG, Ekhator NN, Kasckow JW, Hill KK, Zoumakis E, Dashevsky BA, Chrousos GP and Geracioti TD Jr: Plasma and cerebrospinal fluid interleukin-6 concentrations in posttraumatic stress disorder. Neuroimmunomodulation 9: 209-217, 2001.
32. Nguyen KT, Deak T, Owens SM, Kohno T, Fleshner M, Watkins LR and Maier SF: Exposure to acute stress induces brain interleukin-1β protein in the rat. J Neurosci 18: 2239-2246, 1998.
33. Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M and Barak V: Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 40: 171-176, 1999.
34. Prolla TA: DNA microarray analysis of the aging brain. Chem Senses 27: 299-306, 2002.
35. Choi SH and Suh KY: Interleukin-1 beta,-2,-6 production, serum concentration and hypothalamic-pituitary-adrenal axis in patients with major depression. J Korean Neuropsychiatr Assoc 37: 537-547, 1998.
36. Thomas AJ, Davis S, Morris C, Jackson E, Harrison R and O’Brien JT: Increase in interleukin-1β in late-life depression. Am J Psychiatry 162: 175-177, 2005.
37. Corwin EJ, Johnston N and Pugh L: Symptoms of postpartum depression associated with elevated levels of interleukin-1 beta during the first month postpartum. Biol Res Nurs 10: 128-133, 2008.
38. Ovaskainen Y, Koponen H, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E and Vanhala M: Depressive symptomatology is associated with decreased interleukin-1 beta and increased interleukin-1 receptor antagonist levels in males. Psychiatry Res 167: 73-79, 2009.
39. Cousins RJ and Leinart AS: Tissue-specific regulation of zinc metabolism and metallothionein genes by interleukin 1. FASEB J 2: 2884-2890, 1988.
40. Nolan Y, Maher FO, Martin DS, Clarke RM, Brady MT, Bolton AE, Mills KH and Lynch MA: Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. J Biol Chem 280: 9354-9362, 2005.
41. O’Donovan A, Rush G, Hoatam G, Hughes BM, McCrohan A, Kelleher C, O’Farrelly C and Malone KM: Suicidal ideation is associated with elevated inflammation in patients with major depressive disorder. Depress Anxiety 30: 307-314, 2013.
42. Mesquita AR, Correia-Neves M, Roque S, Castro AG, Vieira P, Pedrosa J, Palha JA and Sousa N: IL-10 modulates depressive-like behavior. J Psychiatr Res 43: 89-97, 2008.
43. Ledeboer A, Brevé JJ, Wierinckx A, van der Jagt S, Bristow AF, Leysen JE, Tilders FJ and Van Dam AM: Expression and regulation of interleukin-10 and interleukin-10 receptor in rat astroglial and microglial cells. Eur J Neurosci 16: 1175-1185, 2002.
44. Ledeboer A, Brevé JJ, Poole S, Tilders FJ and Van Dam AM: Interleukin-10, interleukin-4, and transforming growth factor-β differentially regulate lipopolysaccharide-induced production of pro-inflammatory cytokines and nitric oxide in co-cultures of rat astroglial and microglial cells. Glia 30: 134-142, 2000.
45. Streit WJ, Sammons NW, Kuhns AJ and Sparks DL: Dystrophic microglia in the aging human brain. Glia 45: 208-212, 2004.
46. Kelley KW, O’Connor JC, Lawson MA, Dantzer R, Rodriguez-Zas SL and McCusker RH: Aging leads to prolonged duration of inflammation-induced depression-like behavior caused by Bacillus Calmette-Guérin. Brain Behav Immun 32: 63-69, 2013.
47. Isingrini E, Desmidt T, Belzung C and Camus V: Endothelial dysfunction: A potential therapeutic target for geriatric depression and brain amyloid deposition in Alzheimer’s disease? Curr Opin Investig Drugs 10: 46-55, 2009.
48. Rotheneichner P, Lange S, O’Sullivan A, Marschallinger J, Zaunmair P, Geretsegger C, Aigner L and Couillard-Despres S: Hippocampal neurogenesis and antidepressive therapy: shocking relations. Neural Plast 2014: 723915, 2014.
49. Koo JW and Duman RS: IL-1β is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci USA 105: 751-756, 2008.
50. Samuels BA, Mendez-David I, Faye C, David SA, Pierz KA, Gardier AM, Hen R and David DJ: Serotonin 1A and serotonin 4 receptors: Essential mediators of the neurogenic and behavioral actions of antidepressants. Neuroscientist 22: 26-45, 2016.
51. Ramamoorthy S, Ramamoorthy JD, Prasad PD, Bhat GK, Mahesh VB, Leibach FH and Ganapathy V: Regulation of the human serotonin transporter by interleukin-1 β. Biochem Biophys Res Commun 216: 560-567, 1995.
52. Linthorst AC, Flachskamm C, Müller-Preuss P, Holsboer F and Reul JM: Effect of bacterial endotoxin and interleukin-1 beta on hippocampal serotonergic neurotransmission, behavioral activity, and free corticosterone levels: An in vivo microdialysis study. J Neurosci 15: 2920-2934, 1995.
53. Linthorst AC, Flachskamm C, Holsboer F and Reul JM: Local administration of recombinant human interleukin-1 beta in the rat hippocampus increases serotonergic neurotransmission, hypothalamic-pituitary-adrenocortical axis activity, and body temperature. Endocrinology 135: 520-532, 1994.
54. Shintani F, Kanba S, Nakaki T, Nibuya M, Kinoshita N, Suzuki E, Yagi G, Kato R and Asai M: Interleukin-1 beta augments release of norepinephrine, dopamine, and serotonin in the rat anterior hypothalamus. J Neurosci 13: 3574-3581, 1993.
55. Zhu CB, Blakely RD and Hewlett WA: The proinflammatory cytokines interleukin-1beta and tumor necrosis factor-alpha activate serotonin transporters. Neuropsychopharmacology 31: 2121-2131, 2006.
56. Sperlágh B, Vizi ES, Wirkner K and Illes P: P2X7 receptors in the nervous system. Prog Neurobiol 78: 327-346, 2006.
57. Clark AK, Staniland AA, Marchand F, Kaan TK, McMahon SB and Malcangio M: P2X7-dependent release of interleukin-1β and nociception in the spinal cord following lipopolysaccharide. J Neurosci 30: 573-582, 2010.
58. Seil M, El Ouaaliti M, Abdou Foumekoye S, Pochet S and Dehaye JP: Distinct regulation by lipopolysaccharides of the expression of interleukin-1β by murine macrophages and salivary glands. Innate Immun 18: 14-24, 2012.
59. Roger S, Mei ZZ, Baldwin JM, Dong L, Bradley H, Baldwin SA, Surprenant A and Jiang LH: Single nucleotide polymorphisms that were identified in affective mood disorders affect ATP-activated P2X7 receptor functions. J Psychiatr Res 44: 347-355, 2010.
60. Andó R, Gölöncsér F and Sperlágh B: Modulation of P2X7 receptor function alters depressive behavior in rodent models of depression. Front Neurosci Conference Abstract: IBRO International Workshop 2010, 2010.
61. Basso AM, Bratcher NA, Harris RR, Jarvis MF, Decker MW and Rueter LE: Behavioral profile of P2X7 receptor knockout mice in animal models of depression and anxiety: Relevance for neuropsychiatric disorders. Behav Brain Res 198: 83-90, 2009.
62. Lawson MA, McCusker RH and Kelley KW: Interleukin-1 beta converting enzyme is necessary for development of depression-like behavior following intracerebroventricular administration of lipopolysaccharide to mice. J Neuroinflammation 10: 54, 2013.
63. Leutscher PDC, Lagging M, Buhl MR, Pedersen C, Norkrans G, Langeland N, Mørch K, Färkkilä M, Hjerrild S, Hellstrand K, et al; NORDynamIC Group: Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology 52: 430-435, 2010.
64. Illman J, Corringham R, Robinson D Jr, Davis HM, Rossi JF, Cella D and Trikha M: Are inflammatory cytokines the common link between cancer-associated cachexia and depression? J Support Oncol 3: 37-50, 2005.
65. Xia Z, DePierre JW and Nässberger L: Tricyclic antidepressants inhibit IL-6, IL-1 β and TNF-α release in human blood monocytes and IL-2 and interferon-γ in T cells. Immunopharmacology 34: 27-37, 1996.
66. Musselman DL, Lawson DH, Gumnick JF, Manatunga AK, Penna S, Goodkin RS, Greiner K, Nemeroff CB and Miller AH: Paroxetine for the prevention of depression induced by high-dose interferon alfa. N Engl J Med 344: 961-966, 2001.
67. Lanquillon S, Krieg JC, Bening-Abu-Shach U and Vedder H: Cytokine production and treatment response in major depressive disorder. Neuropsychopharmacology 22: 370-379, 2000.
68. Trask PC, Esper P, Riba M and Redman B: Psychiatric side effects of interferon therapy: Prevalence, proposed mechanisms, and future directions. J Clin Oncol 18: 2316-2326, 2000.
69. Yates WR and Gleason O: Hepatitis C and depression. Depress Anxiety 7: 188-193, 1998.
70. Scheibel RS, Valentine AD, O’Brien S and Meyers CA: Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 16: 185-191, 2004.
71. Gitlin N: Hepatitis B: Diagnosis, prevention, and treatment. Clin Chem 43: 1500-1506, 1997.
72. Horsmans Y: Chronic hepatitis C, depression and interferon. J Hepatol 42: 788-789, 2005.
73. Lotrich FE, Rabinovitz M, Gironda P and Pollock BG: Depression following pegylated interferon-alpha: Characteristics and vulnerability. J Psychosom Res 63: 131-135, 2007.
74. Koprich JB, Reske-Nielsen C, Mithal P and Isacson O: Neuroinflammation mediated by IL-1β increases susceptibility of dopamine neurons to degeneration in an animal model of Parkinson’s disease. J Neuroinflammation 5: 8, 2008.
75. Sulaiman AH, Zainal NZ, Tan KS and Tan CT: Prevalence and associations of post-stroke depression. Neurol J Southeast Asia 7: 71-75, 2002.
76. Broomfield NM, Quinn TJ, Abdul-Rahim AH, Walters MR and Evans JJ: Depression and anxiety symptoms post-stroke/TIA: Prevalence and associations in cross-sectional data from a regional stroke registry. BMC Neurol 14: 198, 2014.
77. Ojagbemi A, Owolabi M, Atalabi M and Baiyewu O: Stroke lesions and post-stroke depression among survivors in Ibadan, Nigeria. Afr J Med Med Sci 42: 245-251, 2013.
78. Herrmann N, Black SE, Lawrence J, Szekely C and Szalai JP: The Sunnybrook Stroke Study: A prospective study of depressive symptoms and functional outcome. Stroke 29: 618-624, 1998.
79. Herrmann LL, Le Masurier M and Ebmeier KP: White matter hyperintensities in late life depression: A systematic review. J Neurol Neurosurg Psychiatry 79: 619-624, 2008.
80. Huang J, Upadhyay UM and Tamargo RJ: Inflammation in stroke and focal cerebral ischemia. Surg Neurol 66: 232-245, 2006.
81. Wiart M, Davoust N, Pialat J-B, Desestret V, Moucharrafie S, Cho TH, Mutin M, Langlois JB, Beuf O, Honnorat J, et al: MRI monitoring of neuroinflammation in mouse focal ischemia. Stroke 38: 131-137, 2007.
82. Tynan RJ, Naicker S, Hinwood M, Nalivaiko E, Buller KM, Pow DV, Day TA and Walker FR: Chronic stress alters the density and morphology of microglia in a subset of stress-responsive brain regions. Brain Behav Immun 24: 1058-1068, 2010.
83. Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, Kubera M, Bob P, Lerer B and Maj M: The inflammatory & neurodegenerative (I&ND) hypothesis of depression: Leads for future research and new drug developments in depression. Metab Brain Dis 24: 27-53, 2009.